Key facts
- This page summarizes Eiry Roberts's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Feb 2025, 18:52.
Eiry Roberts - 08 Feb 2025 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- NBIX
- Reported as of
- 08 Feb 2025
- Net transaction value
- -$115,853
- SEC form
- 4
- Accepted by SEC
- 12 Feb 2025, 18:52:24 UTC
- Prior SEC filing
- 04 Feb 2025
- Next SEC filing
- 14 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Darin Lippoldt, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eiry Roberts filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 12 Feb 2025.
Change
- Previous filing in this sequence was filed on 04 Feb 2025.
- Current net transaction value: -$115,853.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NBIX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +1,860
- Change %
- +5.7%
- Price
- $0.000000
- Shares after
- 34,233
- Date
- 08 Feb 2025
- Ownership
- Direct
NBIX
transaction
Common Stock
Sale
- Transaction value
- $115,853
- Shares
- -980
- Change %
- -2.9%
- Price
- $118.22
- Shares after
- 33,253
- Date
- 10 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NBIX
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -1,860
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 08 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,860
- Exercise price
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Footnote F2
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.07 to $123.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F3
32,068 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
Footnote F4
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F5
This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award.